Agios Pharmaceuticals, Inc. - Common Stock · Transaction Aug 20, 2026 · Filed Sep 10, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · AGIO
-3.54% · -$1.19 · Vol 1.6M
Market closed · last close 4:00 PM ET · price as of 17:26:04 ET
Agios Pharmaceuticals Inc
Biotechnology
$32.42
Follow $AGIO
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $AGIO by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredFri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET · AGIO
MethodologyAGIO
Agios Pharmaceuticals Inc
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
59/ 100
Veridion Score
Middle range · LOW confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is AGIO moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Agios Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
2013
Employees
540
Country
US
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$33.29
Day high
$33.40
Day low
$32.77
Previous close
$33.61
52W high
$45.49
-28.73% from high
52W low
$22.34
44% of range
Market cap
$2B
EPS
$-7.0900
Beta
-0.18
Shares out
59.7M
Volume
1.6M
1.67× rel vol
Avg volume
939.4K
VWAP
$33.07
Price history computed in-house
1W
-3.51%
1M
-2.02%
3M
-7.63%
1Y
-14.00%
YTD
+19.11%
SMA 50 $34.57 · below
SMA 200 $30.72 · above
52W position 44%
AGIO overview
Related filings and maps
Public disclosures
Congress activity in AGIO
Official filing ↗
AGIO · Transaction Mar 3, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000
Agios Pharmaceuticals, Inc. - Common Stock · Transaction Mar 3, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000
AGIO · Transaction Dec 11, 2025 · Filed Jan 12, 2026 · $1,001 to $15,000
Agios Pharmaceuticals, Inc. - Common Stock · Transaction Dec 11, 2025 · Filed Jan 12, 2026 · $1,001 to $15,000
Federal contracts
AGIO contract awards, year to date.
Public federal awards linked to this ticker.
$73.1K
Refresh interval: 12hSource: Federal contract awards
Department of Veterans Affairs
$73.1K
PHARMACEUTICAL AQVESME - 3 MONTH SUPPLY.
PHARMACEUTICAL AQVESME - 3 MONTH SUPPLY.
Jul 14, 2026
Lobbying spend
AGIO lobbying filings, year to date.
Registered lobbying filings matched to Agios Pharmaceuticals Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AGIO in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for AGIO.
Options
Sovereign unlock shows live options positioning for AGIO.